Concepedia

Toward a Single-Dose Cure for Buruli Ulcer

Sangeeta Susan Thomas, Nitin Pal Kalia, Marie‐Thérèse Ruf, Gerd Pluschke, Kévin Pethe

Antimicrobial Agents and Chemotherapy · 2020 · 25 citations · 12 references

DOIFull text

Open access

Concepts

Abstract

A single dose of Q203 (Telacebec), a phase 2 clinical candidate for tuberculosis, eradicates Mycobacterium ulcerans in a mouse model of Buruli ulcer infection without relapse up to 19 weeks posttreatment. Clinical use of Q203 may dramatically simplify the clinical management of Buruli ulcer, a neglected mycobacterial disease.

References

12

A Diarylquinoline Drug Active on the ATP Synthase of <i>Mycobacterium tuberculosis</i>

Koen Andries, Peter Verhasselt, Jérôme Guillemont et al. · Science · 2004 · 2.2K citations · Full text

, , +17

Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis

Kévin Pethe, Pablo Bifani, Jichan Jang et al. · Nature Medicine · 2013 · 614 citations · Full text

, , +7

Reductive evolution and niche adaptation inferred from the genome of <i>Mycobacterium ulcerans</i>, the causative agent of Buruli ulcer

Timothy P. Stinear, Torsten Seemann, Sacha J. Pidot et al. · Genome Research · 2007 · 400 citations · Full text

, , +17

Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial

Richard Odame Phillips, J. Robert, Kabiru Mohamed Abass et al. · The Lancet · 2020 · 110 citations · Full text

, , +10

In Vitro and In Vivo Activities of Rifampin, Streptomycin, Amikacin, Moxifloxacin, R207910, Linezolid, and PA-824 against <i>Mycobacterium ulcerans</i>

Baohong Ji, Sébastien Lefrançois, J. Robert et al. · Antimicrobial Agents and Chemotherapy · 2006 · 109 citations · Full text

, , +13